lupus nephritis
Conditions
Interventions
treatment group:Abatacept 125mg/week subcutaneously
Sponsors
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
16 Years to 85 Years
Inclusion criteria
Inclusion criteria: (1) Patients with lupus nephritis (LN) on abatacept with a diagnosis that meets the criteria for the diagnostic classification of systemic lupus erythematosus (SLE) published jointly by the European League Against Rheumatic Diseases (EULAR) and the American College of Rheumatology (ACR) in 2019, seen at Renji Hospital. (2) Age >16 years. (3) Renal biopsy within 2 years showed lupus nephritis type III, IV, V (alone or in combination with III or IV). (4) 24h urine protein >1g (5)anti-dsDNA= 77 IU/mL (ELISA) or = 20 IU/mL (Farr) or complement C3 25% decrease in estimated glomerular filtration rate [eGFR] from baseline)
Exclusion criteria
Exclusion criteria: (1) Pregnant or lactating women (2) eGFR < 25 ml/minute/1.73 m2 (3) Active infections such as Mycobacterium avium subspecies, presence of hepatitis B surface antigen or hepatitis C antibodies in the blood, evidence of HIV positivity, etc. (4) No treatment with small molecule biologics (e.g., belimumab, rituximab) within 12 weeks prior to enrolment. (5) Have had a malignant tumour within 5 years.(Except for melanoma) (6) Organ transplant recipients (7) Any medical condition during the study period that may interfere with study conduct, interpretation, or patient safety
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| eGFR;24-hour proteinuria;creatinine; | — |
Secondary
| Measure | Time frame |
|---|---|
| SLEDAI-2K;SLE-DAS; | — |
Countries
China
Contacts
Public ContactLiangjing Lu
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed